Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials.

Purpose: Report global adalimumab safety and efficacy outcomes in patients with non-infectious uveitis.

Methods: Adults with non-infectious intermediate, posterior, or panuveitis were randomized 1:1 to receive placebo or adalimumab in the VISUAL I (active uveitis) or VISUAL II (inactive uveitis) trials. Integrated global and Japan substudy results are reported.

Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.

Purpose: To evaluate safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or panuveitis.

Design: Phase 3, open-label, multicenter clinical trial extension (VISUAL III).

Participants: Adults meeting treatment failure (TF) criteria or who completed VISUAL I or II (phase 3, randomized, double-masked, placebo-controlled) without TF.

Prevalence and Incidence of Optic Neuritis in Patients with Different Types of Uveitis.

Purpose: This database study aims to investigate the incidence and prevalence of optic neuritis (ON) among patients with different types of uveitis.

Methods: A retrospective analysis of the Truven Health MarketScan® database from 2000 to 2014 was conducted. Patients with uveitis were followed until diagnosis of ON or until they were censored.

Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.

Purpose: Chronic use of corticosteroids for the treatment of uveitis has been linked with drug-associated toxicity and adverse events (AEs). This study examines the association between corticosteroid dosage and incidence rates of corticosteroid-related AEs.

Design: A post hoc analysis of the VISUAL-1 and VISUAL-2 placebo-controlled clinical trials.

Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.

Importance: Adalimumab was recently approved for the treatment of noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

Objective: To assess the effect of adalimumab on the visual functioning and quality of life in patients with corticosteroid-dependent noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

Design: A post hoc analysis of clinical trials of adults with active (VISUAL-1) and inactive (VISUAL-2) noninfectious intermediate uveitis, posterior uveitis, and panuveitis was conducted in the United States, Canada, Europe, Israel, Australia, Latin America, and Japan.

Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis.

Importance: Noninfectious uveitis (NIU) is a collection of intraocular inflammatory disorders that may be associated with significant visual impairment. To our knowledge, few studies have investigated NIU prevalence overall or stratified by inflammation location, severity, presence of systemic conditions, age, or sex.

Objective: To estimate NIU prevalence using a large, retrospective, administrative claims database.

Adalimumab in Patients with Active Noninfectious Uveitis.

Background: Patients with noninfectious uveitis are at risk for long-term complications of uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid therapy. We conducted a trial to assess the efficacy and safety of adalimumab as a glucocorticoid-sparing agent for the treatment of noninfectious uveitis.

Methods: This multinational phase 3 trial involved adults who had active noninfectious intermediate uveitis, posterior uveitis, or panuveitis despite having received prednisone treatment for 2 or more weeks.

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.

Background: Non-infectious uveitis is a potentially sight-threatening ocular disorder caused by chronic inflammation and its complications. Therapeutic success is limited by systemic adverse effects associated with long-term corticosteroid and immunomodulator use if topical medication is not sufficient to control the inflammation. We aimed to assess the efficacy and safety of adalimumab in patients with inactive, non-infectious uveitis controlled by systemic corticosteroids.

Polychromatic angiography for the assessment of VEGF-induced BRB dysfunction in the rabbit retina.

Purpose: To determine the utility of polychromatic angiography (PCA) in the assessment of VEGF-induced blood retinal barrier (BRB) dysfunction in rabbits.

Methods: Twenty-six eyes of 24 Dutch Belted rabbits were injected intravitreally with 1.25 μg (group A, n = 5), 10 μg (group C, n = 7), or 4 μg (group B, n = 6; group D, n = 4; and group E, n = 4) of VEGF on day 0.

Electroretinography and microperimetry as noninvasive diagnostic tools for cilioretinal artery occlusion.

Purpose: To report a case of cilioretinal artery occlusion with normal fluorescein angiography findings that was evaluated by electroretinography (ERG) and microperimetry.

Methods: A 64-year-old-man presented with an oval paracentral scotoma in the temporal field of the left eye that became more evident after cataract surgery. Fundus photography, fluorescein angiography, ERG, multifocal ERG, and microperimetry were performed.

Functional and structural measurements for the assessment of internal limiting membrane peeling in idiopathic macular pucker.

Objective: To investigate the role of structural and functional measurements in the assessment of internal limiting membrane (ILM) peeling for the treatment of eyes with macular pucker.

Methods: Ten patients with macular pucker who underwent pars plana vitrectomy with ILM peeling were studied prospectively. Visual acuity measurement, standard automated achromatic perimetry, multifocal electroretinography (mfERG), and optical coherence tomography (OCT) were performed before and 3 months after surgery.

Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection.

Purpose: To measure the actual dose of triamcinolone acetonide (TA) delivered during intravitreal injection performed by several common techniques.

Design: Experimental study.

Methods: A 0.

Upregulation of RAGE and its ligands in proliferative retinal disease.

We sought to study the presence of the receptor for advanced glycation endproducts (RAGE) and its ligands, advanced glycation endproducts (AGEs), S100/calgranulins and amphoterin (high mobility group box 1 protein; HMGB1), in the vitreous cavity and epiretinal membranes (ERMs) of eyes of patients with proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR). Undiluted vitreous specimens were collected from 30 eyes of 30 patients undergoing pars plana vitrectomy for repair of retinal detachment (RD) secondary to PDR (n = 15) or PVR (n = 15). The vitreous samples obtained from 10 eyes undergoing macular hole repair were used as controls.